I think we're very supportive of that, of the delisting of those that are obviously being abused through different kinds of systems. I think the challenge is where there's this replacement generic drug that is a replacement that actually has the same potential for addictive properties. So I think we need the same vigilance in making sure that things that replace what has been taken off aren't being used in a similar manner as those that were delisted. I think that's part of the caution we're raising in our briefing as well.
On February 11th, 2014. See this statement in context.